Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Gansu Longshenrongfa Pharmaceutical Industry Co., Ltd. specializes in the production of generic and specialty pharmaceuticals, primarily focusing on the Chinese market. The company benefits from a strong gross margin of 66.5% and a low debt-to-equity ratio of 0.21, positioning it favorably against competitors in the rapidly evolving healthcare sector.
Gansu Longshenrongfa generates revenue through the sale of both generic and specialty pharmaceuticals, leveraging its established distribution channels across China. The company enjoys pricing power due to its strong brand recognition and regulatory approvals, which create barriers for new entrants.
Changes in regulatory approvals for new drugs
Market share shifts in the Chinese pharmaceutical sector
Pricing pressures from generic competitors
Supply chain disruptions affecting raw material costs
Regulatory changes impacting drug approvals and pricing
Technological disruptions in drug development processes
Increased competition from domestic and international generic manufacturers
Potential for new entrants leveraging advanced technologies
Low liquidity due to negative free cash flow
Dependence on successful product launches to drive revenue
moderate - The pharmaceutical sector is somewhat insulated from economic downturns, but consumer spending on healthcare can be influenced by GDP growth.
Low - The company has low debt levels, so rising interest rates will have minimal impact on financing costs. However, higher rates could affect consumer spending on non-essential medications.
minimal - The company operates with a low debt-to-equity ratio, reducing reliance on credit markets.
growth - Investors are likely attracted to the potential for revenue growth from new product launches and market expansion.
moderate - The stock has shown a 1-year return of 8.5%, indicating some stability but with potential for fluctuations based on market conditions.
